Table 2 Methylation status of VDAC2 in human sperm in NZ and IAS group.

From: Abnormal Hypermethylation of the VDAC2 Promoter is a Potential Cause of Idiopathic Asthenospermia in Men

Groups

Status of methylation

CpG1 a%(n/N)

CpG2a%(n/N)

CpG3a%(n/N)

CpG4a%(n/N)

CpG5a%(n/N)

CpG6a%(n/N)

CpG7a%(n/N)

NZ

Complete unmethylation (0%)**

74.07%(200/270)

76.67%(207/270)

75.19%(203/270)

86.30%(233/270)

86.67%(234/270)

84.81%(229/270)

90.37%(244/270)

Mild methylation (0–20%)*

7.41%(20/270)

8.15%(22/270)

9.26%(25/270)

6.67%(18/270)

11.85%(32/270)

10.74%(29/270)

7.04%(19/270)

Moderate methylation (20–80%)**

18.52%(50/270)

15.19%(41/270)

15.56%(42/270)

7.04%(19/270)

1.48%(4/270)

4.44%(12/270)

2.59%(7/270)

Severe methylation (80–100%)

0

0

0

0

0

0

0

Total (N)

270

270

270

270

270

270

270

Groups

Status of methylation

CpG1a%(n/N)

CpG2a%(n/N)

CpG3a%(n/N)

CpG4a%(n/N)

CpG5a%(n/N)

CpG6a%(n/N)

CpG7a%(n/N)

IAS

Complete unmethylation (0%)

64.00%(160/250)

69.20%%(173/250)

63.60%(159/250)

80.80%(202/250)

75.60%(189/250)

72.80%(182/250)

80.80%(202/250)

Mild methylation (0–20%)

3.60%(9/250)

6.40%(16/250)

4.00%(10/250)

6.40%(16/250)

6.00%(15/250)

4.40%(11/250)

8.80%(22/250)

Moderate methylation (20–80%)

32.40%(81/250)

24.40%(61/250)

29.20%(73/250)

12.80%(32/250)

18.40%(46/250)

22.80%(57/250)

10.40%(26/250)

Severe methylation (80–100%)

0

0

3.20% (8/250)

0

0

0

0

Total (N)

250

250

250

250

250

250

250

Groups

Status of methylation

CpG8a%(n/N)

CpG9a%(n/N)

CpG10a%(n/N)

CpG11a%(n/N)

CpG12a%(n/N)

CpG13a%(n/N)

CpG14a%(n/N)

NZ

Complete unmethylation (0%)**

88.15%(238/270)

80.74%(218/270)

89.26%(241/270)

77.78%(210/270)

88.15%(238/270)

83.33 (225/270)

89.63%(242/270)

Mild methylation (0–20%)*

8.15%(22/270)

8.15%(22/270)

8.15%(22/270)

9.26%(25/270)

8.15%(22/270)

10.00%(27/270)

9.26%(25/270)

Moderate methylation (20–80%)**

3.70%(10/270)

11.11%(30/270)

2.59%(7/270)

12.96%(35/270)

3.70%(10/270)

6.67%(18/270)

1.11%(3/270)

Severe methylation (80–100%)

0

0

0

0

 

0

0

Total (N)

270

270

270

270

270

270

270

Groups

Status of methylation

CpG1a%(n/N)

CpG2a%(n/N)

CpG3a%(n/N)

CpG4a%(n/N)

CpG5a%(n/N)

CpG6a%(n/N)

CpG7a%(n/N)

IAS

Complete unmethylation (0%)

81.60%(204/250)

76.40%(191/250)

85.20%(213/250)

69.60%(174/250)

80.80%(202/250)

72.80%(182/250)

86.40%(216/250)

Mild methylation (0–20%)

8.00%(20/250)

8.80%(22/250)

10.40%(26/250)

5.60%(14/250)

8.00%(20/250)

6.40%(16/250)

9.60%(24/250)

Moderate methylation (20–80%)

10.40%(26/250)

14.80%(37/250)

4.40%(11/250)

24.80%(62/250)

11.20%(28/250)

20.80%(52/250)

4.00%(10/250)

Severe methylation (80–100%)

0

0

0

0

0

0

0

Total (N)

250

250

250

250

250

250

250

  1. CpG:—C—phosphate—G—; NZ: normozoospermia; IAS: idiopathic asthenospermia; Statistically significant differences from the control group (NZ) were represented with asterisks: *P < 0.05, **P < 0.01.